Recurrent and Metastatic Head and Neck Cancers
Publication Date: December 15, 2022
Key Points
Key Points
- Head and neck cancers frequently arise from the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx, and more rarely from salivary glands or paranasal sinuses.
- Immune-checkpoint inhibitors (ICIs) are now approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with or without chemotherapy.
- The guideline provides recommendations regarding immunotherapy and biomarker testing for this diverse and complex group of diseases.
Treatment
...atment...
...ommendation 1.1Programmed death-ligand 1 (PD-...
...endation 1.2PD-L1 combined positive score (CPS)...
...mendation 1.3Tumor mutational burden (TMB) tes...
...mmendation 1.4TMB ≥10 should be in...
...ion 2.1Pembrolizumab monotherapy or pembrolizuma...
...ommendation 2.2Pembrolizumab, platinu...
...3.1Pembrolizumab or nivolumab should be offere...
...commendation 4.1Toripalimab, camrelizumab or...
...mmendation 4.2Programmed cell death protein 1 (PD...
...ommendation 5.1For patients with oligometastatic...
...endation 6.1Pembrolizumab may be offered to pat...
Recommendation 6.2Pembrolizumab ma...
...omarkers and Recommendations by PD-L1 St...
Figure 2. Recommendations by Subt...